- Temocaprilat
-
- $1.10
-
2026-08-20
- CAS:110221-53-9
- Min. Order: 1g
- Purity: 99.9% Min
- Supply Ability: 100 Tons
- Temocaprilat
-
- $198.00
-
2026-07-27
- CAS:110221-53-9
- Purity: 99.31%
- Supply Ability: 10g
|
| | Temocaprilat Basic information |
| Product Name: | Temocaprilat | | Synonyms: | [3H]-Temocaprilat;RS-5139;TEMOCAPRILAT(FORR&DONLY);(+)-[(2S,6R)-6-[[(S)-1-(Ethoxycarbonyl)-3-phenylpropyl]amino]-5-oxo-2-(2-thienyl)perhydro-1,4-thiazepin-4-yl]acetic acid;[[[2S,6R]-6-[[(S)-1-Carboxy-3-phenylpropyl]amino]hexahydro-5-oxo-2-(2-thienyl)-1,4-thiazepin]-4-yl]acetic acid;(2S,6R)-6-[[(1S)-1-Carboxy-3-phenylpropyl]amino]tetrahydro-5-oxo-2-(2-thienyl)-1,4-thiazepine-4(5H)-acetic Acid;Temocapril Diacid;Temocaprilate | | CAS: | 110221-53-9 | | MF: | C21H24N2O5S2 | | MW: | 448.56 | | EINECS: | | | Product Categories: | Intermediates & Fine Chemicals;Pharmaceuticals | | Mol File: | 110221-53-9.mol |  |
| | Temocaprilat Chemical Properties |
| Melting point | >2300C (dec) | | alpha | 25D +63.4° (c = 1 in DMF) | | Boiling point | 743.6±60.0 °C(Predicted) | | density | 1.41±0.1 g/cm3(Predicted) | | storage temp. | Sealed in dry,2-8°C | | solubility | DMSO (Slightly), Methanol (Slightly) | | form | Solid | | pka | 2.09±0.10(Predicted) | | color | White to Off-White |
| | Temocaprilat Usage And Synthesis |
| Description | Temocaprilat is an inhibitor of angiotensin-converting enzyme (ACE; IC50 = 3.6 nM for rabbit lung ACE). It inhibits contraction of isolated rat aorta induced by angiotensin I with an IC50 value of 7.6 nM. Temocaprilat (1-30 μg/kg, i.v.) inhibits angiotensin I-induced pressor responses in anesthetized rats in a dose-dependent manner. | | Chemical Properties | White to Off-White Solid | | Uses | Antihypertensive. | | Definition | ChEBI: Temocaprilat is a non-proteinogenic alpha-amino acid. | | in vivo | Temocaprilat (1 mg/kg/d; i.v.; 4 weeks) significantly reduces systolic blood pressure with time-dependent manner in spontaneously hypertensive (SHR) rats. Temocaprilat improves myocardial fibrosis and oxidative stress in Wistar-Kyoto (WKY) rats and SHR rats[3]. | Animal Model: | Six 10-week-old WKYs and SHRs and six 50-week-old (aging control) SHRs[3]. | | Dosage: | 1 mg/kg/d. | | Administration: | Intravenous injection; 4 weeks. | | Result: | Reduced the expression levels of myocardial fibrosis, transforming growth factor-β1 (TGF-β1) mRNA and fibroblast growth factor-2 (FGF-2) mRNA in the left ventricle (LV).
Weakened the expression levels of 8-isoprostane, p22phox mRNA, p47phox mRNA and gp91phox mRNA in LV.
|
| | References | [1] KIYOSHI OIZUMI . Pharmacological Profiles of CS-622, a Novel Angiotensin Converting Enzyme Inhibitor[J]. Japanese journal of pharmacology, 1988, 48 3: Pages 349-356. DOI: 10.1254/jjp.48.349 |
| | Temocaprilat Preparation Products And Raw materials |
|